Contract Research, Development & Manufacturing (Biologics, Liquid Small Molecules)
Total Trials
2
As Lead Sponsor
0
As Collaborator
Total Enrollment
66
NCT04895449
Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19
Phase: Phase 1
Role: Collaborator
Start: Jul 16, 2021
Completion: Nov 8, 2022
NCT05226390
Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate
Start: Feb 24, 2022
Completion: Nov 21, 2023
Loading map...